Protagonist Therapeutics, Inc. — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. Although the request references 2023 Q4, this filing is an annual report covering the full fiscal year. The company is a clinical-stage biopharmaceutical developer with no approved products or product sales revenue. Its lead programs are rusfertide for polycythemia vera and JNJ-2113 for inflammatory diseases.
Business Context and Pipeline
- Rusfertide: Injectable hepcidin mimetic in development for polycythemia vera. Phase 2 REVIVE and PACIFIC studies produced positive results, including durable hematocrit control and reduced phlebotomy use. The global Phase 3 VERIFY trial was ongoing, with enrollment expected to conclude by the end of the first quarter of 2024.
- JNJ-2113: Oral IL-23 receptor antagonist being developed by Johnson & Johnson. Phase 2b FRONTIER 1 in plaque psoriasis achieved its primary and secondary endpoints. JNJ initiated multiple Phase 3 psoriasis trials and a Phase 2b ulcerative colitis trial.
- PN-943: Phase 2 ulcerative colitis development was completed in early 2023, and the company does not intend to commit further internal clinical development or contract manufacturing resources to the program.
- The company also has preclinical programs involving oral hepcidin mimetics and an oral IL-17 peptide antagonist.
Financial Performance and Liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| License and collaboration revenue | $60.0 million | $26.6 million | Up 126% |
| Research and development expense | $120.2 million | $126.2 million | Down 5% |
| General and administrative expense | $33.5 million | $31.7 million | Up 6% |
| Total operating expenses | $153.7 million | $158.0 million | Down 3% |
| Loss from operations | $(93.7) million | $(131.4) million | Improved by $37.7 million |
| Interest income | $14.9 million | $4.1 million | Up 267% |
| Net loss | $(79.0) million | $(127.4) million | Improved by $48.4 million |
| Net loss per share | $(1.39) | $(2.60) | Improved |
| Cash used in operating activities | $(70.2) million | $(108.1) million | Improved by $37.9 million |
- The $60.0 million of 2023 revenue primarily reflected a $50.0 million JNJ milestone related to the ICONIC-TOTAL Phase 3 trial and a $10.0 million JNJ milestone related to the ANTHEM-UC Phase 2b trial.
- Rusfertide clinical and development expense increased 51% to $98.1 million, primarily reflecting Phase 3 VERIFY activity. PN-943 expense declined 97% to $1.1 million.
- Stock-based compensation was $29.3 million, including $17.1 million in research and development and $12.2 million in general and administrative expense.
- At December 31, 2023, cash and cash equivalents were $186.7 million, marketable securities were $154.9 million, and total cash, cash equivalents and marketable securities were $341.6 million.
- Total assets were $358.0 million and stockholders’ equity was $336.7 million. No traditional debt is reported; current operating lease liabilities were $1.1 million, with a remaining lease obligation of approximately $1.2 million.
- Management stated that existing cash, cash equivalents and marketable securities were expected to fund operations for at least the next 12 months based on the current operating plan.
Material Changes Versus the Prior Comparable Period
- Revenue increased substantially because of JNJ development milestones, while the company remained dependent on collaboration payments rather than product sales.
- Net loss and operating cash burn declined materially, aided by higher collaboration revenue, lower PN-943 spending and increased interest income.
- R&D spending shifted toward rusfertide: rusfertide expense increased by $33.3 million, while PN-943 expense decreased by $35.8 million.
- The company raised approximately $107.8 million net through an April 2023 public offering, $24.3 million through its ATM facility and $34.4 million through warrant-related transactions. Shares outstanding increased to 57.7 million at year-end from 49.3 million.
- In January 2024, after year-end, the company entered into a worldwide rusfertide collaboration with Takeda. The agreement was not yet effective as of the filing date and was subject to applicable Hart-Scott-Rodino waiting-period requirements.
Guidance, Outlook, Risks and Unusual Items
- Under the Takeda agreement, the company expects a $300 million upfront payment, up to $330 million of development, regulatory and commercial milestones, and tiered royalties of 10% to 17% on ex-U.S. net sales. The parties expect to share U.S. profits and losses equally, subject to the company’s opt-out right.
- The company expects to fund rusfertide development through completion of VERIFY and U.S. regulatory approval. It expects results from the ongoing two-year rat carcinogenicity study by the end of 2024.
- JNJ-2113 remains dependent on JNJ’s execution of multiple ongoing clinical trials. Protagonist is eligible for approximately $795.0 million of future JNJ development and sales milestones and tiered royalties of 6% to 10% on net product sales.
- Rusfertide previously experienced a three-week FDA clinical hold in 2021 after tumor findings in a mouse carcinogenicity study. The hold was lifted after additional safety information, monitoring procedures and stopping rules were provided. The filing notes prior human cancer cases and ongoing carcinogenicity evaluation.
- The company has no approved products, no historical commercial product revenue and expects continued operating losses. Additional capital may be required, and future equity financing could dilute shareholders.
- Material risks include clinical-trial failure or delay, patient enrollment challenges, regulatory non-approval, adverse safety findings, reliance on JNJ and Takeda, third-party CRO and manufacturing dependence, competition, intellectual-property disputes, reimbursement uncertainty and macroeconomic or supply-chain disruption.
- The company reported no material pending legal proceedings and received unqualified audit opinions on its financial statements and internal control over financial reporting.
Most Important Facts for Investors to Verify
- Whether the Takeda agreement became effective and whether the $300 million upfront payment was received.
- VERIFY enrollment completion, Phase 3 results, regulatory interactions and the outcome of the rusfertide carcinogenicity study.
- JNJ-2113 enrollment progress, Phase 3 efficacy and safety results, and the probability and timing of future JNJ milestones.
- The company’s cash runway after incorporating VERIFY spending, commercial preparation costs and any Takeda-related receipts.
- Potential dilution from outstanding options, restricted stock units, performance units and 2.7 million pre-funded warrants outstanding at December 31, 2023.
- Whether prior rusfertide safety findings, injection-site reactions or future cancer signals could affect labeling, approval or commercial adoption.
- The extent to which future revenue depends on milestone payments rather than recurring product sales or royalties.